))
Evaluating Prophylactic Anticoagulant Therapy Effectiveness for Treating COVID-19
Fetch error
Hmmm there seems to be a problem fetching this series right now.
Last successful fetch was on May 20, 2024 23:09 (
What now? This series will be checked again in the next day. If you believe it should be working, please verify the publisher's feed link below is valid and includes actual episode links. You can contact support to request the feed be immediately fetched.
Manage episode 302555367 series 2309938
Content provided by VA HSRD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by VA HSRD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
In this episode, Dr. Christopher Rentsch, of the London School of Hygiene and Tropical Medicine and Yale University, talks about a large-scale evaluation of the effectiveness of prophylactic anticoagulant therapy for the treatment of COVID-19.
Since the recording of this podcast, the largest trial to date, ACTIV-4, has found that initiating therapeutic anticoagulation compared to prophylactic anticoagulation provided additional benefit among patients hospitalized with COVID-19. Both Dr. Rentsch’s study and the ACTIV-4 study found benefit in noncritically ill patients yet not in critically ill patients.
…
continue reading
Since the recording of this podcast, the largest trial to date, ACTIV-4, has found that initiating therapeutic anticoagulation compared to prophylactic anticoagulation provided additional benefit among patients hospitalized with COVID-19. Both Dr. Rentsch’s study and the ACTIV-4 study found benefit in noncritically ill patients yet not in critically ill patients.
48 episodes
Share
